Biotech & Food Systems: Navigating the Commercial Scaling Inflection Point

The speculative venture capital bubble that defined the early alternative protein and food biotechnology sector has undergone a necessary and healthy market correction. The initial wave of funding, which valued consumer-facing food-tech startups on software-like multiples, overlooked the fundamental reality that food production is an intensive industrial engineering challenge. As the market transitions away from branding hype, Mayview Capital sees a compelling opportunity to deploy structured growth equity at the industrial scaling inflection point.

The Industrial Engineering Deficit

The scientific fundamentals of cellular agriculture, precision fermentation, and plant protein restructuring have been thoroughly validated in laboratory and pilot-scale environments. The core challenge facing the industry is no longer biological discovery, but the engineering complexity of transitioning from a 10-litre laboratory vessel to a 100,000-litre continuous commercial production line.

The sector's primary bottlenecks are structural and capital-intensive:

• The CAPEX Bottleneck: Building dedicated, food-grade precision fermentation and extrusion facilities requires substantial upfront capital. Many early-stage businesses attempted to build proprietary manufacturing footprints, severely depleting their balance sheets and leaving them vulnerable when equity markets tightened.
• The Path to Price Parity: While consumer interest in alternative nutrition remains stable, sustained adoption is constrained by pricing. Achieving cost parity with highly optimised, conventional agricultural supply chains requires manufacturing processes that run continuously at a massive, automated scale.
• Sensory and Functional Consistency: Delivering products that meet consumer expectations for taste, texture, and performance requires advanced ingredient formulation. Achieving this consistency at an industrial scale demands sophisticated process control and high-quality raw feedstocks.

The B2B Enablement Layer as a Defensive Investment Thesis

For Mayview Capital, the investment thesis has shifted entirely away from consumer brands (B2C) toward the B2B enablement and infrastructure layers of the agricultural value chain. Rather than taking on the high customer-acquisition costs and brand-building risks of individual food products, we target the critical infrastructure and intellectual property that power the entire sector.

Our investment framework focuses on contract manufacturing organisations (CMOs) that provide shared, multi-tenant processing capacity, allowing brand owners to scale production without incurring prohibitive capital expenditure.

Additionally, Mayview Capital targets companies developing high-margin functional ingredients – such as specialised plant proteins, natural enzymes, and algae-derived fats, which improve the nutritional profile and sensory performance of alternative foods. By focusing on the essential processing assets and proprietary formulations of the food system, Mayview Capital secures defensive, high-margin exposure to a critical global transition, turning scientific innovation into robust, scalable industrial realities.